Fewer cytomegalovirus complications after kidney transplantation byde novouse of mTOR inhibitors in comparison to mycophenolic acid-Reference-Cited by-同舟云学术

Fewer cytomegalovirus complications after kidney transplantation byde novouse of mTOR inhibitors in comparison to mycophenolic acid

Published:2016-02 Issue:1 Volume:18 Page:79-88
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Radtke J.¹,Dietze N.¹,Spetzler V.N.¹,Fischer L.¹,Achilles E.-G.¹,Li J.¹,Scheidat S.²,Thaiss F.²,Nashan B.¹,Koch M.¹

Affiliation:

1. Department of Hepatobiliary and Transplant Surgery; University Medical Center Hamburg-Eppendorf UKE; University Transplantation-Center UTC; Hamburg Germany

2. Department of Internal Medicine III; University Medical Center Hamburg-Eppendorf UKE; University Transplantation-Center UTC; Hamburg Germany

Funder

Novartis

Astellas Pharma US

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tid.12494/fullpdf

Reference38 articles.

1. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation;Nett;Transplantation,2004

2. Cytomegalovirus infection renal transplant recipients: risk factors and outcome;Kanter;Transplant Proc,2009

3. Current characteristics and outcome of cytomegalovirus infections after kidney transplantation;Helanterä;Transpl Infect Dis,2014

4. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients;Tedesco Silva;Am J Transplant,2010

5. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms;Brennan;Rev Med Virol,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QuantiFERON-CMV as a Predictor of CMV Events During Preemptive Therapy in CMV-seropositive Kidney Transplant Recipients;Transplantation;2023-11-22

2. Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy;Frontiers in Transplantation;2023-11-21

3. Nierentransplantation;Die Chirurgie;2023-11-16

4. The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation;Xenotransplantation;2023-04-07

5. Risk factors for cytomegalovirus infection and disease after kidney transplantation: A meta-analysis;Transplant Immunology;2022-10